Financial Health Check: Examining Hims & Hers Health Inc (HIMS)’s Key Ratios

Kiel Thompson

The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.

Hims & Hers Health Inc (NYSE: HIMS) closed the day trading at $34.67 down -0.37% from the previous closing price of $34.8. In other words, the price has decreased by -$0.37 from its previous closing price. On the day, 4.92 million shares were traded. HIMS stock price reached its highest trading level at $35.04 during the session, while it also had its lowest trading level at $34.1301.

Ratios:

For a better understanding of HIMS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.53 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 67.99. For the most recent quarter (mrq), Quick Ratio is recorded 1.64 and its Current Ratio is at 1.88. In the meantime, Its Debt-to-Equity ratio is 1.92 whereas as Long-Term Debt/Eq ratio is at 1.92.

Upgrades & Downgrades

In the most recent recommendation for this company, Barclays on December 09, 2025, initiated with a Overweight rating and assigned the stock a target price of $48.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 22 ’25 when Okupe Oluyemi sold 23,090 shares for $35.72 per share. The transaction valued at 824,710 led to the insider holds 94,333 shares of the business.

Oluyemi Okupe bought 32,160 shares of HIMS for $1,127,208 on Dec 22 ’25. On Dec 17 ’25, another insider, Chi Michael, who serves as the Chief Operating Officer of the company, sold 13,750 shares for $36.71 each. As a result, the insider received 504,762 and left with 305,161 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HIMS now has a Market Capitalization of 7892573696 and an Enterprise Value of 8380852736. As of this moment, Hims’s Price-to-Earnings (P/E) ratio for their current fiscal year is 64.10, and their Forward P/E ratio for the next fiscal year is 57.95. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.73. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.57 while its Price-to-Book (P/B) ratio in mrq is 13.58. Its current Enterprise Value per Revenue stands at 3.791 whereas that against EBITDA is 49.737.

Stock Price History:

The Beta on a monthly basis for HIMS is 2.35, which has changed by 0.30534637 over the last 52 weeks, in comparison to a change of 0.16098404 over the same period for the S&P500. Over the past 52 weeks, HIMS has reached a high of $72.98, while it has fallen to a 52-week low of $23.97. The 50-Day Moving Average of the stock is -15.39%, while the 200-Day Moving Average is calculated to be -24.25%.

Shares Statistics:

Over the past 3-months, HIMS traded about 23.75M shares per day on average, while over the past 10 days, HIMS traded about 10655900 shares per day. A total of 219.12M shares are outstanding, with a floating share count of 206.49M. Insiders hold about 9.29% of the company’s shares, while institutions hold 89.50% stake in the company. Shares short for HIMS as of 1765756800 were 64816789 with a Short Ratio of 2.73, compared to 1763078400 on 67552266. Therefore, it implies a Short% of Shares Outstanding of 64816789 and a Short% of Float of 35.22.

Earnings Estimates

A detailed examination of Hims & Hers Health Inc (HIMS) is currently in progress, with 11.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $0.15, with high estimates of $0.3 and low estimates of $0.1.

Analysts are recommending an EPS of between $0.58 and $0.38 for the fiscal current year, implying an average EPS of $0.48. EPS for the following year is $0.66, with 11.0 analysts recommending between $1.37 and $0.33.

Revenue Estimates

12 analysts predict $617.48M in revenue for. The current quarter. It ranges from a high estimate of $624.72M to a low estimate of $608.22M. As of. The current estimate, Hims & Hers Health Inc’s year-ago sales were $481.14MFor the next quarter, 12 analysts are estimating revenue of $658.67M. There is a high estimate of $673.8M for the next quarter, whereas the lowest estimate is $630.7M.

A total of 14 analysts have provided revenue estimates for HIMS’s current fiscal year. The highest revenue estimate was $2.35B, while the lowest revenue estimate was $2.33B, resulting in an average revenue estimate of $2.35B. In the same quarter a year ago, actual revenue was $1.48BBased on 13 analysts’ estimates, the company’s revenue will be $2.77B in the next fiscal year. The high estimate is $2.94B and the low estimate is $2.52B.

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.